Key Drivers
- Very high margins
- Weakening cash
- Low leverage
AIAI Summary
Doximity's strategic pivot from cash‑generative SaaS to an AI‑led growth story materially alters the investment thesis — upside hinges on proving repeatable AI monetization without further margin erosion while the key near‑term risk is continued revenue weakness from concentrated pharma spending and falling operating cash. Investors should watch quarterly guidance, top‑20 NRR, operating cash flow, and AI revenue scale over the next 12–24 months as binary catalysts to upgrade or downgrade the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very high margins
- •Weakening cash
- •Low leverage
DOCS combines extremely high gross and operating margins with strong ROIC/ROE but faces a material cash drawdown, rising receivables and declining deferred revenue that could pressure near-term cash conversion. #high-margins #cash-risk
Price Behavior
Key Price Behavior Insights:
- •Modest downtrend
- •Nearby floor
- •High volatility
Over the last month the stock slipped from $25.55 to $24.41, showing a modest short-term downtrend with nearby support around $23.7–$24 and resistance at $26.4–$27 amid elevated intraperiod volatility.
Frequent swings between ~$23.8 and ~$27 increased execution risk
Sentiment & News
Key News Insights:
- •High AI adoption
- •Big holder rebalancing
- •Disappointing guidance
Doximity shows strong physician AI engagement and solid SaaS economics but faces mixed institutional flows and caution after disappointing near-term guidance.
Product relevance and analyst support temper downside, but near-term guidance and large stake cuts make shares prone to continued volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings